{"id":3468,"date":"2023-07-18T17:52:05","date_gmt":"2023-07-18T23:52:05","guid":{"rendered":"https:\/\/udibi6748.live-website.com\/?page_id=3468"},"modified":"2023-07-18T17:53:02","modified_gmt":"2023-07-18T23:53:02","slug":"anti-pd1","status":"publish","type":"page","link":"https:\/\/udibi.com.mx\/en\/anti-pd1\/","title":{"rendered":"Anti-PD1"},"content":{"rendered":"

[vc_row][vc_column][vc_custom_heading text=”Anti-PD1″ font_container=”tag:h2|font_size:35|text_align:left|color:%230d1250″ google_fonts=”font_family:Montserrat%3Aregular%2C700|font_style:700%20bold%20regular%3A700%3Anormal”][vc_column_text]Antibodies that target checkpoint inhibitors have demonstrated high effectiveness as a therapy for treating cancer, with PD-1 (Programmed cell death protein 1) being one of the most successful targets for developing antibody-based drugs. PD-1 is expressed on the surface of T and B lymphocytes and transmits inhibitory signals upon binding to its ligands, PD-L1 and PD-L2, which are expressed on macrophages and dendritic cells. PD-L1\/L2 are also highly expressed in various cancer cells, leading to immune evasion by tumor cells. Therefore, blocking the interaction between PD-1 and PD-L1\/L2 with monoclonal antibodies unleashes the immune system to effectively destroy cancer cells.<\/p>\n

In this project, we employed a fully synthetic phage display library to generate a panel of anti-PD-1 antibodies with diverse binding and functional profiles. Through three rounds of selection using recombinant PD-1 as the target, a total of 315 clones were tested for their ability to bind PD-1. Among these clones, 143 demonstrated specificity for PD-1, with 60 of them being unique. Further characterization of this panel of PD-1 binders allowed the identification of the best-performing clones, which were then converted to IgG4PE format. One such antibody, named D6, exhibited the ability to block the PD-1:PD-L1\/L2 interaction in ELISA and Jurkat cells, while showing no cross-reactivity with molecules related to the CD28 family. Notably, D6 also promoted the expression of Interferon gamma in a mixed lymphocyte reaction co-culture assay, similar to FDA-approved therapeutic antibodies Keytruda and Obdivo.<\/p>\n

Based on these findings, D6 appears to be a promising lead candidate for the development of an antibody-based drug targeting checkpoint inhibitors as a therapy for cancer treatment.[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

[vc_row][vc_column][vc_custom_heading text=”Anti-PD1″ font_container=”tag:h2|font_size:35|text_align:left|color:%230d1250″ google_fonts=”font_family:Montserrat%3Aregular%2C700|font_style:700%20bold%20regular%3A700%3Anormal”][vc_column_text]Antibodies that target checkpoint inhibitors have demonstrated high effectiveness as a therapy for treating cancer, with PD-1 (Programmed cell death protein 1) being one of the most successful targets for developing antibody-based drugs. PD-1 is expressed on the surface of T and B lymphocytes and transmits inhibitory signals upon binding to its ligands, PD-L1 and PD-L2, which […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"pmpro_default_level":"","footnotes":""},"class_list":["post-3468","page","type-page","status-publish","hentry","pmpro-has-access"],"yoast_head":"\nAnti-PD1 - UDIBI<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/udibi.com.mx\/en\/anti-pd1\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Anti-PD1 - UDIBI\" \/>\n<meta property=\"og:description\" content=\"[vc_row][vc_column][vc_custom_heading text=”Anti-PD1″ font_container=”tag:h2|font_size:35|text_align:left|color:%230d1250″ google_fonts=”font_family:Montserrat%3Aregular%2C700|font_style:700%20bold%20regular%3A700%3Anormal”][vc_column_text]Antibodies that target checkpoint inhibitors have demonstrated high effectiveness as a therapy for treating cancer, with PD-1 (Programmed cell death protein 1) being one of the most successful targets for developing antibody-based drugs. PD-1 is expressed on the surface of T and B lymphocytes and transmits inhibitory signals upon binding to its ligands, PD-L1 and PD-L2, which […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/udibi.com.mx\/en\/anti-pd1\/\" \/>\n<meta property=\"og:site_name\" content=\"UDIBI\" \/>\n<meta property=\"article:modified_time\" content=\"2023-07-18T23:53:02+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/udibi.com.mx\/en\/anti-pd1\/\",\"url\":\"https:\/\/udibi.com.mx\/en\/anti-pd1\/\",\"name\":\"Anti-PD1 - UDIBI\",\"isPartOf\":{\"@id\":\"https:\/\/udibi.com.mx\/en\/#website\"},\"datePublished\":\"2023-07-18T23:52:05+00:00\",\"dateModified\":\"2023-07-18T23:53:02+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/udibi.com.mx\/en\/anti-pd1\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/udibi.com.mx\/en\/anti-pd1\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/udibi.com.mx\/en\/anti-pd1\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\/\/udibi.com.mx\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Anti-PD1\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/udibi.com.mx\/en\/#website\",\"url\":\"https:\/\/udibi.com.mx\/en\/\",\"name\":\"UDIBI\",\"description\":\"IPN\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/udibi.com.mx\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Anti-PD1 - UDIBI","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/udibi.com.mx\/en\/anti-pd1\/","og_locale":"en_US","og_type":"article","og_title":"Anti-PD1 - UDIBI","og_description":"[vc_row][vc_column][vc_custom_heading text=”Anti-PD1″ font_container=”tag:h2|font_size:35|text_align:left|color:%230d1250″ google_fonts=”font_family:Montserrat%3Aregular%2C700|font_style:700%20bold%20regular%3A700%3Anormal”][vc_column_text]Antibodies that target checkpoint inhibitors have demonstrated high effectiveness as a therapy for treating cancer, with PD-1 (Programmed cell death protein 1) being one of the most successful targets for developing antibody-based drugs. PD-1 is expressed on the surface of T and B lymphocytes and transmits inhibitory signals upon binding to its ligands, PD-L1 and PD-L2, which […]","og_url":"https:\/\/udibi.com.mx\/en\/anti-pd1\/","og_site_name":"UDIBI","article_modified_time":"2023-07-18T23:53:02+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/udibi.com.mx\/en\/anti-pd1\/","url":"https:\/\/udibi.com.mx\/en\/anti-pd1\/","name":"Anti-PD1 - UDIBI","isPartOf":{"@id":"https:\/\/udibi.com.mx\/en\/#website"},"datePublished":"2023-07-18T23:52:05+00:00","dateModified":"2023-07-18T23:53:02+00:00","breadcrumb":{"@id":"https:\/\/udibi.com.mx\/en\/anti-pd1\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/udibi.com.mx\/en\/anti-pd1\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/udibi.com.mx\/en\/anti-pd1\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/udibi.com.mx\/en\/"},{"@type":"ListItem","position":2,"name":"Anti-PD1"}]},{"@type":"WebSite","@id":"https:\/\/udibi.com.mx\/en\/#website","url":"https:\/\/udibi.com.mx\/en\/","name":"UDIBI","description":"IPN","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/udibi.com.mx\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/udibi.com.mx\/en\/wp-json\/wp\/v2\/pages\/3468","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/udibi.com.mx\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/udibi.com.mx\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/udibi.com.mx\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/udibi.com.mx\/en\/wp-json\/wp\/v2\/comments?post=3468"}],"version-history":[{"count":2,"href":"https:\/\/udibi.com.mx\/en\/wp-json\/wp\/v2\/pages\/3468\/revisions"}],"predecessor-version":[{"id":3470,"href":"https:\/\/udibi.com.mx\/en\/wp-json\/wp\/v2\/pages\/3468\/revisions\/3470"}],"wp:attachment":[{"href":"https:\/\/udibi.com.mx\/en\/wp-json\/wp\/v2\/media?parent=3468"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}